The estimated Net Worth of Michael Damon Hutchinson is at least $3.7 Million dollars as of 30 March 2024. Mr. Hutchinson owns over 1,478 units of Varian Medical Systems stock worth over $46,761 and over the last 10 years he sold VAR stock worth over $3,650,915. In addition, he makes $0 as Senior Vice President and Chief Legal Officer at Varian Medical Systems.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Hutchinson VAR stock SEC Form 4 insiders trading
Michael has made over 9 trades of the Varian Medical Systems stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,478 units of VAR stock worth $24,439 on 30 March 2024.
The largest trade he's ever made was selling 15,995 units of Varian Medical Systems stock on 6 February 2019 worth over $2,886,938. On average, Michael trades about 2,515 units every 165 days since 2015. As of 30 March 2024 he still owns at least 2,828 units of Varian Medical Systems stock.
You can see the complete history of Mr. Hutchinson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Hutchinson biography
Michael Damon Hutchinson serves as Senior Vice President, Chief Legal Officer of the Company. Most recently, Mr. Hutchinson served as Vice President and Advisor to the Chairman and CEO at Stryker. Prior to this role, he served as General Counsel, Vice President and Chief Legal Officer at Stryker, overseeing the global Legal & Compliance organization and the corporate secretary function, and guiding the company through more than 80 acquisitions over the span of 10 years. He began his career working for several law firms and as an in-house attorney in the Washington, D.C. , area. He holds a law degree from George Washington University Law School and a bachelor's degree from Clark University.
How old is Michael Hutchinson?
Michael Hutchinson is 49, he's been the Senior Vice President and Chief Legal Officer of Varian Medical Systems since 2020. There are 11 older and 2 younger executives at Varian Medical Systems. The oldest executive at Varian Medical Systems, Inc. is David Illingworth, 66, who is the Independent Director.
What's Michael Hutchinson's mailing address?
Michael's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W26LG.
Insiders trading at Varian Medical Systems
Over the last 21 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin, and Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.
What does Varian Medical Systems's logo look like?
Complete history of Mr. Hutchinson stock trades at LivaNova PLC, Stryker, and Varian Medical Systems
Varian Medical Systems executives and stock owners
Varian Medical Systems executives and other stock owners filed with the SEC include:
-
Dow Wilson,
Chief Executive Officer, Director -
Kolleen Kennedy,
President - Proton Solutions Division and Chief Growth Officer -
Chris Toth,
President, Chief Operating Officer -
R. Andrew Eckert,
Independent Chairman of the Board -
Jeffrey Balser,
Independent Director -
Judy Bruner,
Independent Director -
Anat Ashkenazi,
Independent Director -
Jean-Luc Butel,
Independent Director -
Regina Dugan,
Independent Director -
David Illingworth,
Independent Director -
Phillip Febbo,
Independent Director -
Michael Hutchinson,
Senior Vice President, Chief Legal Officer -
Francis Facchini,
President, Interventional Solutions Business -
Anshul Maheshwari,
Vice President, Treasurer and Investor Relations -
Michelle Le Beau,
Independent Director -
J. Michael Bruff,
Chief Financial Officer, Senior Vice President - Finance -
Magnus Momsen,
SVP, CAO, Corporate Controller -
Mark R Laret,
Director -
Jose Baselga,
Director -
John W Kuo,
SVP, Gen Counsel and Secretary -
Gary E Jr Bischoping,
SVP, Finance & CFO -
Susan L Bostrom,
Director -
Timothy E Guertin,
Director -
Clarence R Verhoef,
SVP, Finance, Corp Controller -
Venkatraman Thyagarajan,
Director -
Sunny Sanyal,
SVP and President, ICB -
Robert H Kluge,
Corporate Vice President -
Richard M Levy,
President and CEO -
Ruediger Naumann Etienne,
Director -
John Seely Brown,
Director -
Erich R Reinhardt,
Director -
Tai Yun Chen,
VP and Corporate Controller -
David W Jr Martin,
Director -
Steven A Leibel,
Director -
Kent J Thiry,
Director -
Allen S Lichter,
Director -
Samuel Hellman,
Director -
Crisanto C Raimundo,
Corporate Controller -
Terry R Lautenbach,
Director -
Joseph B Phair,
VP Admin,Gen Counsel,Secretary -
Elisha W Finney,
Corporate Vice President & CFO -
Kevin O'reilly,
SVP, President of Oncology Sys